Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Emanuel Bührer, Michal Kiciński, Mario Mandalà, Madeline Pe, Georgina V Long, Victoria Atkinson, Christian U. Blank, Andrew Haydon, Stéphane Dalle, Adnan Khattak, Matteo S. Carlino, Andrey Meshcheryakov, Shahneen Sandhu, Susana Puig, Dirk Schadendorf, Rahima Jamal, Piotr Rutkowski, Alfonsus Johannes Maria van den Eertwegh, Corneel Coens, Dmitri Grebennik, Clemens Krepler, Caroline Robert, Alexander M.M. Eggermont (2024). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. , 25(9), DOI: https://doi.org/10.1016/s1470-2045(24)00338-3.
